A citation-based method for searching scientific literature

Charalampos Aktypis, Maria-Eleni Spei, Maria Yavropoulou, Göran Wallin, Anna Koumarianou, Gregory Kaltsas, Eva Kassi, Kosmas Daskalakis. Cancers (Basel) 2021
Times Cited: 2







List of co-cited articles
articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond.
Maria E Cabanillas, Mabel Ryder, Camilo Jimenez. Endocr Rev 2019
94
50

Cabozantinib in progressive medullary thyroid cancer.
Rossella Elisei, Martin J Schlumberger, Stefan P Müller, Patrick Schöffski, Marcia S Brose, Manisha H Shah, Lisa Licitra, Barbara Jarzab, Viktor Medvedev, Michael C Kreissl,[...]. J Clin Oncol 2013
658
50

The association between clinician-based common terminology criteria for adverse events (CTCAE) and patient-reported outcomes (PRO): a systematic review.
Thomas M Atkinson, Sean J Ryan, Antonia V Bennett, Angela M Stover, Rebecca M Saracino, Lauren J Rogak, Sarah T Jewell, Konstantina Matsoukas, Yuelin Li, Ethan Basch. Support Care Cancer 2016
169
50

RET oncogene in MEN2, MEN2B, MTC and other forms of thyroid cancer.
Maya B Lodish, Constantine A Stratakis. Expert Rev Anticancer Ther 2008
62
50


Can nurses' shift work jeopardize the patient safety? A systematic review.
M Di Muzio, S Dionisi, E Di Simone, C Cianfrocca, F Di Muzio, F Fabbian, G Barbiero, D Tartaglini, N Giannetta. Eur Rev Med Pharmacol Sci 2019
23
50

A comprehensive overview of the role of the RET proto-oncogene in thyroid carcinoma.
Cristina Romei, Raffaele Ciampi, Rossella Elisei. Nat Rev Endocrinol 2016
162
50

Effects of epidermal growth factor receptor inhibitor-induced dermatologic toxicities on quality of life.
Smita S Joshi, Sara Ortiz, Joslyn N Witherspoon, Alfred Rademaker, Dennis P West, Roger Anderson, Sara E Rosenbaum, Mario E Lacouture. Cancer 2010
122
50

Impact of dermatologic adverse events on quality of life in 283 cancer patients: a questionnaire study in a dermatology referral clinic.
Alyx C Rosen, Emily C Case, Stephen W Dusza, Yevgeniy Balagula, Jennifer Gordon, Dennis P West, Mario E Lacouture. Am J Clin Dermatol 2013
98
50

Information support, illness perceptions, and distress in survivors of differentiated thyroid cancer.
Chelsea H Wiener, Jeffrey E Cassisi, Daniel Paulson, Olga Husson, Rema A Gupta. J Health Psychol 2019
15
50

Accuracy and knowledge in 12-lead ECG placement among nursing students and nurses: a web-based Italian study.
Noemi Giannetta, Giuseppe Campagna, Flavio Di Muzio, Emanuele Di Simone, Sara Dionisi, Marco Di Muzio. Acta Biomed 2020
2
50

Prognostic indicators of outcomes in patients with distant metastases from differentiated thyroid carcinoma.
Margo Shoup, Alexander Stojadinovic, Aviram Nissan, Ronald A Ghossein, Sam Freedman, Murray F Brennan, Jatin P Shah, Ashok R Shaha. J Am Coll Surg 2003
176
50

Cabozantinib and vandetanib for unresectable locally advanced or metastatic medullary thyroid cancer: a systematic review and economic model.
Paul Tappenden, Christopher Carroll, Jean Hamilton, Eva Kaltenthaler, Ruth Wong, Jonathan Wadsley, Laura Moss, Sabapathy Balasubramanian. Health Technol Assess 2019
17
50

Comparative Effectiveness of Generic vs Brand-Name Levothyroxine in Achieving Normal Thyrotropin Levels.
Juan P Brito, Joseph S Ross, Lindsey Sangaralingham, Sarah K Dutcher, David J Graham, Zhong Wang, Yute Wu, Xiaoxi Yao, Robert C Smallridge, Victor Bernet,[...]. JAMA Netw Open 2020
13
50

Vandetanib for the treatment of patients with locally advanced or metastatic hereditary medullary thyroid cancer.
Samuel A Wells, Jessica E Gosnell, Robert F Gagel, Jeffrey Moley, David Pfister, Julie A Sosa, Michael Skinner, Annetta Krebs, James Vasselli, Martin Schlumberger. J Clin Oncol 2010
347
50


Hyperglycemia Associated With Targeted Oncologic Treatment: Mechanisms and Management.
Jonathan W Goldman, Melody A Mendenhall, Sarah R Rettinger. Oncologist 2016
24
50

Health care providers underestimate symptom intensities of cancer patients: a multicenter European study.
Eivor A Laugsand, Mirjam A G Sprangers, Kristin Bjordal, Frank Skorpen, Stein Kaasa, Pål Klepstad. Health Qual Life Outcomes 2010
180
50

Home blood-pressure monitoring in patients receiving sunitinib.
Michel Azizi, Antoine Chedid, Stéphane Oudard. N Engl J Med 2008
132
50


Acalabrutinib: Managing Adverse Events and Improving Adherence in Patients With Mantle Cell Lymphoma.
Maria Badillo, Diana Nava, Maria Rosa, Wendy Chen, Maria Guerrero, Michael Wang. Clin J Oncol Nurs 2020
4
50



Expert opinion on the metabolic complications of new anticancer therapies: Tyrosine kinase inhibitors.
Perrine Buffier, Benjamin Bouillet, Sarra Smati, Francoise Archambeaud, Bertrand Cariou, Bruno Verges. Ann Endocrinol (Paris) 2018
14
50

The rapid assessment of fatigue severity in cancer patients: use of the Brief Fatigue Inventory.
T R Mendoza, X S Wang, C S Cleeland, M Morrissey, B A Johnson, J K Wendt, S L Huber. Cancer 1999
50

Vandetanib in patients with locally advanced or metastatic medullary thyroid cancer: a randomized, double-blind phase III trial.
Samuel A Wells, Bruce G Robinson, Robert F Gagel, Henning Dralle, James A Fagin, Massimo Santoro, Eric Baudin, Rossella Elisei, Barbara Jarzab, James R Vasselli,[...]. J Clin Oncol 2012
849
50

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
50

Incidence and risk of hypertension with vandetanib in cancer patients: a systematic review and meta-analysis of clinical trials.
Wei-xiang Qi, Zan Shen, Feng Lin, Yuan-jue Sun, Da-liu Min, Li-na Tang, Ai-na He, Yang Yao. Br J Clin Pharmacol 2013
64
50

MASCC/ISOO clinical practice guidelines for the management of mucositis secondary to cancer therapy.
Rajesh V Lalla, Joanne Bowen, Andrei Barasch, Linda Elting, Joel Epstein, Dorothy M Keefe, Deborah B McGuire, Cesar Migliorati, Ourania Nicolatou-Galitis, Douglas E Peterson,[...]. Cancer 2014
589
50

Challenges associated with tyrosine kinase inhibitor therapy for metastatic thyroid cancer.
Maria E Cabanillas, Mimi I Hu, Jean-Bernard Durand, Naifa L Busaidy. J Thyroid Res 2011
46
50

The physician-patient working alliance: Theory, research, and future possibilities.
Jairo N Fuertes, Arielle Toporovsky, Mariela Reyes, Jennifer Bennett Osborne. Patient Educ Couns 2017
48
50

Caregiver Well-being and the Quality of Cancer Care.
Kristin Litzelman. Semin Oncol Nurs 2019
16
50

Loneliness and quality of life after head and neck cancer.
A Dahill, Helen Al-Nakishbandi, K B Cunningham, G M Humphris, D Lowe, S N Rogers. Br J Oral Maxillofac Surg 2020
10
50

Clinical factors associated with worse quality-of-life scores in United States thyroid cancer survivors.
Sneha Goswami, Benjamin J Peipert, Michael N Mongelli, Sasha K Kurumety, Irene B Helenowski, Susan E Yount, Cord Sturgeon. Surgery 2019
36
50

Vandetanib in advanced medullary thyroid cancer: review of adverse event management strategies.
Enrique Grande, Michael C Kreissl, Sebastiano Filetti, Kate Newbold, Walter Reinisch, Caroline Robert, Martin Schlumberger, Lærke K Tolstrup, Jose L Zamorano, Jaume Capdevila. Adv Ther 2013
35
50




Targeted Therapy in Thyroid Cancer: State of the Art.
L Valerio, L Pieruzzi, C Giani, L Agate, V Bottici, L Lorusso, V Cappagli, L Puleo, A Matrone, D Viola,[...]. Clin Oncol (R Coll Radiol) 2017
68
50


Initial assessment, surveillance, and management of blood pressure in patients receiving vascular endothelial growth factor signaling pathway inhibitors.
Michael L Maitland, George L Bakris, Henry R Black, Helen X Chen, Jean-Bernard Durand, William J Elliott, S Percy Ivy, Carl V Leier, Joann Lindenfeld, Glenn Liu,[...]. J Natl Cancer Inst 2010
265
50

Vandetanib in children and adolescents with multiple endocrine neoplasia type 2B associated medullary thyroid carcinoma.
Elizabeth Fox, Brigitte C Widemann, Meredith K Chuk, Leigh Marcus, Alberta Aikin, Patricia O Whitcomb, Maria J Merino, Maya Lodish, Eva Dombi, Seth M Steinberg,[...]. Clin Cancer Res 2013
94
50

Treatment of advanced thyroid cancer with targeted therapies: ten years of experience.
David Viola, Laura Valerio, Eleonora Molinaro, Laura Agate, Valeria Bottici, Agnese Biagini, Loredana Lorusso, Virginia Cappagli, Letizia Pieruzzi, Carlotta Giani,[...]. Endocr Relat Cancer 2016
105
50


2015 American Thyroid Association Management Guidelines for Adult Patients with Thyroid Nodules and Differentiated Thyroid Cancer: The American Thyroid Association Guidelines Task Force on Thyroid Nodules and Differentiated Thyroid Cancer.
Bryan R Haugen, Erik K Alexander, Keith C Bible, Gerard M Doherty, Susan J Mandel, Yuri E Nikiforov, Furio Pacini, Gregory W Randolph, Anna M Sawka, Martin Schlumberger,[...]. Thyroid 2016
50

Lenvatinib for Radioactive Iodine-Refractory Differentiated Thyroid Carcinoma and Candidate Biomarkers Associated with Survival: A Multicenter Study in Korea.
Eyun Song, Mijin Kim, Eui Young Kim, Bo Hyun Kim, Dong Yeob Shin, Ho-Cheol Kang, Byeong-Cheol Ahn, Won Bae Kim, Young Kee Shong, Min Ji Jeon,[...]. Thyroid 2020
20
50

Treatment compliance and severe adverse events limit the use of tyrosine kinase inhibitors in refractory thyroid cancer.
Alexandra Chrisoulidou, Stylianos Mandanas, Efterpi Margaritidou, Lemonia Mathiopoulou, Maria Boudina, Konstantinos Georgopoulos, Kalliopi Pazaitou-Panayiotou. Onco Targets Ther 2015
19
50



Management of sorafenib-related adverse events: a clinician's perspective.
Marcia S Brose, Catherine T Frenette, Stephen M Keefe, Stacey M Stein. Semin Oncol 2014
78
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.